New Zealand markets closed

G1 Therapeutics, Inc. (GTHX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.17+0.23 (+4.66%)
At close: 04:00PM EDT
5.61 +0.44 (+8.51%)
After hours: 07:50PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 228.47M
Enterprise value 127.58M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.40
Price/book (mrq)2.28
Enterprise value/revenue 5.28
Enterprise value/EBITDA -0.78

Trading information

Stock price history

Beta (5Y monthly) 2.03
52-week change 3-75.14%
S&P500 52-week change 3-11.93%
52-week high 321.62
52-week low 33.84
50-day moving average 35.00
200-day moving average 39.59

Share statistics

Avg vol (3-month) 31.11M
Avg vol (10-day) 31.81M
Shares outstanding 542.71M
Implied shares outstanding 6N/A
Float 835.9M
% held by insiders 19.10%
% held by institutions 168.27%
Shares short (14 Jun 2022) 47.75M
Short ratio (14 Jun 2022) 46.62
Short % of float (14 Jun 2022) 420.39%
Short % of shares outstanding (14 Jun 2022) 418.14%
Shares short (prior month 12 May 2022) 46.4M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 0.00%
Operating margin (ttm)-677.58%

Management effectiveness

Return on assets (ttm)-38.84%
Return on equity (ttm)-99.02%

Income statement

Revenue (ttm)24.16M
Revenue per share (ttm)0.57
Quarterly revenue growth (yoy)-51.50%
Gross profit (ttm)29.46M
EBITDA -163.24M
Net income avi to common (ttm)-171.1M
Diluted EPS (ttm)-4.03
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)183.02M
Total cash per share (mrq)4.29
Total debt (mrq)82.12M
Total debt/equity (mrq)82.02
Current ratio (mrq)5.95
Book value per share (mrq)2.35

Cash flow statement

Operating cash flow (ttm)-143.41M
Levered free cash flow (ttm)-80.03M